Blend Labs, Inc. (BLND): Nasdaq/NYSE listing notice — Blend Labs receives NYSE delisting notice; average stock price below $1.00 for 30 trading days

Blend Labs, Inc.

NYSE notified Blend on April 28, 2023, of non-compliance with Section 802.01C due to avg closing price <$1.00 over 30 days.
Company has six months from receipt to regain compliance; possible cure includes a reverse stock split if needed.
Stock continues trading on NYSE; notice does not affect business operations or SEC reporting obligations.
Blend plans to notify NYSE of intent to cure within 10 business days and is pursuing business initiatives to drive share price.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Blend Labs, Inc. received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01C).

Exchange: nyse
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 802.01C

Exact text from the filing

April 28, 2023, Blend Labs, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that as of April 27, 2023 it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the min

View on SEC.gov

Browse all listing & compliance notices →

Blend Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001855747-23-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.